INTRODUCTION {#s1}
============

Liver cancer is one of the most common human malignancies and most primary liver cancers occurring worldwide are hepatocellular carcinoma (HCC) \[[@R1]\]. Surgery is the only potentially curative treatment option for patients who have resectable HCC. Unfortunately, even after surgery, the 5-year overall survival (OS) rate is estimated to 50% and the 5-year recurrence rate exceeds 70% \[[@R2], [@R3]\] .Thus, it is crucial to explore and identify biomarkers for predicting the prognosis in HCC patients after surgery.

Systemic inflammatory response is increasingly recognized to play decisive roles at different stages of tumor development, including initiation, promotion, malignant conversion, invasion, and metastasis \[[@R4]\]. Previous studies reported the systemic inflammatory response was associated with cancer progression \[[@R5]\]. Recently there has been increasing interest in improving cancer prognostication using inflammatory biomarkers. The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), have both been demonstrated to be prognostic markers for patients with various types of tumors \[[@R6]-[@R14]\]. Previous studies of hematologic malignancies suggested that an increased LMR indicate a good prognosis \[[@R15], [@R16]\]. There have been a few reports focusing on the prognostic significance of LMR in patients with solid tumors, including gastric \[[@R17]\], colon\[[@R18]\], bladder\[[@R19],[@R20]\], renal\[[@R21]\] and lung cancers \[[@R22]\].

Gamma-glutamyltransferase (GGT) plays an important role in the metabolism of glutathione. GGT was investigated as a liver enzyme and a high level of serum GGT has been usually deemed as an alert sign for potential liver disease clinically. Recently, some studies suggested elevated GGT was a promising biomarker for poor OS of HCC patients who underwent hepatic resection \[[@R23]\], radiofrequency-ablation treatment \[[@R24]\] or transcatheter arterial chemoembolization \[[@R25]\].

In this study, we created a systemic inflammation score (SIS) basing on preoperative serum GGT and LMR. It may serve as a better prognostic predictor for clinical outcome in HCC patients after hepatectomy. We conducted this retrospective study in a large cohort of HCC patients undergoing potentially curative resection, attempting to investigate the prognostic value of the systemic inflammatory biomarkers in HCC patients undergoing curative resection.

RESULTS {#s2}
=======

Clinicopathological characteristics {#s2_1}
-----------------------------------

Clinical and pathologic characteristics of all patients were summarized in Table [1](#T1){ref-type="table"}. Of the 271 patients, 213 (78.6%) were males and 58 (21.4%) were females. The median age of the entire cohort was 60 years (range, 27-81 years). The median follow-up was 26 months (range, 5 to 101 months). The mean preoperative GGT was 102.37±146.79 (U/L). The mean platelet, absolute lymphocyte and absolute monocyte counts were 188.36±64.92(×10^9^L^-1^), 1.61±0.56 (×10^9^L^-1^) and 0.45±0.20 (×10^9^L^-1^), respectively. The mean LMR was 4.09±1.99.

###### Association of LMR,GGT and SIS with clinicopathological characteristics

                          Total   LMR   GGT   SIS                                           
  ----------------------- ------- ----- ----- ------- ----- ----- --------- ---- ----- ---- ---------
  Age(year)                                   0.157               0.909                     0.602
  ≤50                     106     61    45            50    56              26   43    37   
  \>50                    165     109   56            79    86              32   71    62   
  Sex                                         0.179               0.002                     0.014
  Female                  58      32    26            38    20              19   26    13   
  Male                    213     138   75            91    122             39   88    86   
  HBsAg                                       0.477               0.077                     0.107
  Positive                218     139   79            98    120             41   95    82   
  Negative                53      31    22            31    22              17   19    17   
  AFP                                         0.084               0.046                     0.517
  ≤20μg/L                 101     70    31            56    45              20   47    34   
  \>20μg/L                170     100   70            73    97              38   67    65   
  TB                                          0.056               0.479                     0.229
  ≤17.1umol/L             265     164   101           127   138             58   112   95   
  \>17.1umol/L            6       6     0             2     4               0    2     4    
  Albumin                                     0.069               0.058                     0.049
  ≤40 g/L                 102     71    31            41    61              15   42    45   
  \>40 g/L                169     99    70            88    81              43   72    54   
  ALT                                         0.393               0.001                     0.007
  ≤40 U/L                 221     136   85            116   105             51   99    71   
  \>40 U/L                50      34    16            13    37              7    15    28   
  AST                                         0.064               \<0.001                   \<0.001
  ≤40 U/L                 230     139   91            121   109             54   104   72   
  \>40 U/L                41      31    10            8     33              4    10    27   
  Liver cirrhosis                             0.064               0.063                     0.136
  No                      41      31    10            25    16              6    23    12   
  Yes                     230     139   91            104   126             52   91    87   
  Tumor size                                  0.215               \<0.001                   0.001
  ≤5 cm                   121     71    50            76    45              35   56    30   
  \>5 cm                  150     99    51            53    97              23   58    69   
  Tumor number                                0.069               0.118                     0.834
  Single                  207     136   71            104   103             45   85    77   
  Mutiple                 64      34    30            25    39              13   29    22   
  Tumor encapsulation                         0.937               0.018                     0.181
  Complete                135     85    50            74    61              31   62    42   
  None                    136     85    51            55    81              27   52    57   
  Vascular invasion                           0.903               0.131                     0.647
  No                      181     114   67            92    89              41   77    63   
  Yes                     90      56    34            37    53              17   37    36   
  Tumor differentiation                       0.997               0.163                     0.612
  I+II                    169     106   63            86    83              38   73    58   
  III+IV                  102     64    38            43    59              20   41    41   
  TNM stage                                   0.020               \<0.001                   0.001
  I                       210     124   86            112   98              53   92    65   
  II+III                  61      46    15            17    44              5    22    34   

Abbreviations: AFP=alpha fetoprotein; ALT=alanine aminotransferase; AST=aspartate transaminase; GGT=gamma-glutamyltransferase; HBsAg=hepatitis B surface antigen; LMR= lymphocyte-to-monocyte ratio; SIS=systemic inflammation score; TB= total bilirubin; TNM = tumor--node--metastasis.

The optimal cut-off value for LMR {#s2_2}
---------------------------------

The optimal cut-off value of LMR was determined by the receiver operating characteristic (ROC) curve analysis for OS. The cut-off value was 4.5 when OS was employed as end-point for LMR, which yielded the largest sensitivity and specificity. LMR was stratified into \< 4.5 or ≥4.5 for subsequent analyses. 170 patients (62.7%) and 101 patients (37.3%) were included in the low-LMR group ( \< 4.5) and high-LMR group (≥4.5), respectively.

Systemic inflammation score (SIS) evaluation {#s2_3}
--------------------------------------------

The continuous variable GGT was stratified into \< 50 or ≥50 U/L and the continuous variable LMR was stratified into \< 4.5 or ≥4.5 for subsequent analyses. Kaplan-Meier analysis indicated that the high-GGT and low-LMR were both associated with shorter OS (*P* \< 0.001 for both). In order to further discriminate patients with different outcome, we subsequently dichotomized patients into four subgroups basing on serum GGT and LMR levels. In subgroups of either high-GGT or low-LMR, the OS was not different significantly (*P* = 0.518). Therefore, these two subgroups were combined and SIS was scored as follows: Patients with low-GGT and high-LMR were allocated a score of 0, patients with either high-GGT or low-LMR were allocated a score of 1, and patients with both high-GGT and low-LMR were allocated a score of 2.

Associations of LMR, GGT and SIS with clinicopathological characteristics {#s2_4}
-------------------------------------------------------------------------

The clinicopathological characteristics grouped by LMR, GGT and SIS were summarized in Table [1](#T1){ref-type="table"}. In patients with HCC, LMR was associated with TNM stage (*P* = 0.020). Elevated GGT was associated with male (*P* = 0.002), alpha fetoprotein(AFP)\>20μg/L (*P* = 0.046), ALT\>40U/L (*P* = 0.001), AST\>40U/L (*P* \< 0.001), tumor size \>5 cm (*P* \< 0.001), tumor encapsulation (*P* = 0.018) and TNM stage (*P* \< 0.001). SIS was significantly associated with sex (*P* = 0.014), albumin (*P* = 0.049), ALT (*P* = 0.007), AST (*P* \< 0.001), tumor size (*P* = 0.001) and TNM stage (*P* = 0.001).

Analysis of the prognostic impact of LMR, GGT and SIS {#s2_5}
-----------------------------------------------------

The median OS of the entire cohort was 29.3 months and 5-year OS was 36.6 %. The median time to recurrence (TTR) of the entire cohort was 18.0 months. The relationships between preoperative LMR, GGT, and OS and TTR were shown in Figgure [1](#F1){ref-type="fig"}. An elevated preoperative LMR was significantly associated with increased OS (*P* \< 0.001, Figure [1A](#F1){ref-type="fig"}) and TTR (*P* = 0.022, Figure [1B](#F1){ref-type="fig"}). Whereas an elevated preoperative GGT was significantly associated with inferior OS (*P* \< 0.001, Fig. [1C](#F1){ref-type="fig"}) and TTR (*P* = 0.005, Figure [1D](#F1){ref-type="fig"}). In addition, low SIS was significantly associated with increased OS (*P* \< 0.001, Figure [2A](#F2){ref-type="fig"}) and TTR (*P* = 0.005, Figure [2B](#F2){ref-type="fig"}). The 1-, 3-, and 5-year OS rates of patients with SIS = 0 (89.5%, 65.9%, and 52.6%, respectively) were significantly higher than patients with SIS = 1 (76.3%, 52.2%, and 38.5%, respectively) and SIS = 2 (63.6%, 26.8%, and 25.1%, respectively). Moreover, the 1-, 3-, and 5-year cumulative recurrence rates of patients with SIS = 0 were 27.6%, 44.2%, and 52.7%, respectively, which were significantly lower than those of SIS = 1 (44.0%, 61.7%, and 65.4%, respectively) and SIS = 2 (53.3%, 69.5%, and 74.6%, respectively).

![Kaplan-Meier analyses for overall survival and cumulative recurrence rate of HCC patients based on preoperative LMR and GGT](oncotarget-08-79366-g001){#F1}

![Kaplan-Meier analyses for overall survival and cumulative recurrence rate of HCC patients based on SIS](oncotarget-08-79366-g002){#F2}

Evaluation of the prognostic factors for OS and TTR using the Cox proportional hazard model {#s2_6}
-------------------------------------------------------------------------------------------

The results of univariate and multivariate Cox regression analyses of the factors related to OS and TTR were summarize in Table [2](#T2){ref-type="table"}. Univariate analysis indicated that ALT, AST, tumor size, tumor encapsulation, vascular invasion, TNM stage, absolute lymphocyte counts, absolute monocyte counts, LMR, GGT and SIS were significant prognostic factors for OS, and tumor number, tumor encapsulation, vascular invasion, TNM stage, LMR, GGT and SIS were significant prognostic factors for TTR. Two multivariate models were performed separately, considering that SIS is constructed based on GGT and LMR. Multivariate analysis indicated that ALT, tumor encapsulation, vascular invasion, TNM stage, LMR, GGT and SIS were independent prognostic factors for OS, and tumor number, tumor encapsulation, vascular invasion, TNM stage, LMR and SIS were independent prognostic factors for TTR.

###### Univariate and multivariate Cox proportional hazards regression analysis for OS and TTR

                                            OS                   TTR                            
  ----------------------------------------- -------------------- --------- -------------------- ---------
  ***Univariate analysis***                                                                     
  Age ,year(\>50y vs. ≤50)                  1.110(0.775-1.589)   0.569     1.072(0.777-1.480)   0.672
  Sex(male vs. female)                      1.413(0.884-2.260)   0.148     1.305(0.866-1.965)   0.203
  HBsAg(negative vs. positive)              0.853(0.546-1.331)   0.483     1.071(0.726-1.580)   0.729
  AFP, μg/L(\>20 vs. ≤20)                   1.008(0.702-1.449)   0.964     1.094(0.786-1.523)   0.593
  TB, umol/L(\>17.1 vs. ≤17.1)              1.290(0.457-3.642)   0.631     0.491(0.121-1.982)   0.318
  Albumin, g/L(\>40 vs. ≤40)                0.772(0.538-1.107)   0.159     0.875(0.632-1.212)   0.421
  ALT, U/L(\>40 vs. ≤40)                    1.713(1.139-2.576)   0.010     1.041(0.687-1.577)   0.852
  AST, U/L(\>40 vs. ≤40)                    2.156(1.417-3.281)   \<0.001   1.465(0.959-2.237)   0.077
  Liver cirrhosis(yes vs. no)               1.316(0.788-2.198)   0.294     1.412(0.873-2.284)   0.159
  Tumor size,cm(\>5 vs. ≤5)                 1.786(1.239-2.574)   0.002     1.366(0.992-1.881)   0.056
  Tumor number (multiple vs. single)        1.278(0.846-1.929)   0.243     1.934(1.365-2.740)   \<0.001
  Tumor encapsulation (complete vs. none)   1.973(1.379-2.822)   \<0.001   1.511(1.101-2.075)   0.011
  Vascular invasion(yes vs. no)             2.174(1.530-3.090)   \<0.001   1.707(1.237-2.356)   0.001
  Tumor differentiation(III+IV vs I+II)     1.079(0.753-1.548)   0.678     1.283(0.931-1.770)   0.128
  TNM stage (II+III vs. I)                  2.252(1.525-3.328)   \<0.001   1.880(1.311-2.697)   0.001
  Absolute lymphocyte counts^1^             0.679(0.493-0.934)   0.017     0.866(0.652-1.150)   0.321
  Absolute monocyte counts^1^               2.599(1.083-6.232)   0.032     1.931(0.876-4.257)   0.103
  Absolute platelet counts^1^               1.001(0.999-0.004)   0.297     1.001(0.998-1.003)   0.636
  LMR (≥4.5 vs. \<4.5)                      0.450(0.301-0.673)   \<0.001   0.680(0.487-0.949)   0.023
  GGT,U/L (≥50 vs. \<50)                    2.619(1.805-3.801)   \<0.001   1.562(1.136-2.147)   0.006
  SIS                                                                                           
   0                                        Reference                      Reference            
   1                                        1.913(1.051-3.481)   0.034     1.544(0.987-2.416)   0.057
   2                                        4.695(2.631-8.378)   \<0.001   2.124(1.348-3.347)   0.001
  ***Multivariate analysis*** ^2^                                                               
  ALT, U/L(\>40 vs. ≤40)                    1.995(1.100-3.618)   0.023     NA                   
  AST, U/L(\>40 vs. ≤40)                    0.899(0.501-1.615)   0.899     NA                   
  Tumor size,cm(\>5 vs. ≤5)                 0.972(0.601-1.572)   0.909     NA                   
  Tumor number (multiple vs. single)        NA                             2.139(1.495-3.061)   \<0.001
  Tumor encapsulation (complete vs. none)   1.952(1.341-2.843)   \<0.001   1.547(1.122-2.132)   0.008
  Vascular invasion(yes vs. no)             2.026(1.329-3.089)   0.001     1.684(1.216-2.332)   0.002
  TNM stage (II+III vs. I)                  1.770(1.150-2.726)   0.010     1.589(1.097-2.303)   0.014
  Absolute lymphocyte counts                0.807(0.534-1.222)   0.311     NA                   
  Absolute monocyte counts                  0.600(0.178-2.024)   0.600     NA                   
  LMR (≥4.5 vs. \<4.5)                      0.467(0.273-0.800)   0.006     0.614(0.433-0.870)   0.006
  GGT,U/L (≥50 vs. \<50)                    1.963(1.293-2.981)   0.002     1.228(0.886-1.702)   0.217
  ***Multivariate analysis*** ^3^                                                               
  ALT, U/L(\>40 vs. ≤40)                    1.963(1.085-3.552)   0.026     NA                   
  AST, U/L(\>40 vs. ≤40)                    0.885(0.494-1.586)   0.885     NA                   
  Tumor size,cm(\>5 vs. ≤5)                 0.956(0.598-1.528)   0.850     NA                   
  Tumor number (multiple vs. single)        NA                             2.055(1.444-2.923)   \<0.001
  Tumor encapsulation (complete vs. none)   1.960(1.347-2.851)   \<0.001   1.514(1.100-2.083)   0.011
  Vascular invasion(yes vs. no)             2.056(1.348-3.136)   0.001     1.657(1.197-2.293)   0.002
  TNM stage (II+III vs. I)                  1.764(1.146-2.716)   0.010     1.585(1.094-2.295)   0.015
  Absolute lymphocyte counts                0.791(0.542-1.155)   0.225     NA                   
  Absolute monocyte counts                  0.611(0.192-1.949)   0.405     NA                   
  SIS                                                                                           
   0                                        Reference                      Reference            
   1                                        1.680(0.900-3.137)   0.103     1.460(0.930-2.291)   0.100
   2                                        3.784(1.865-7.680)   \<0.001   1.996(1.249-3.190)   0.004

Abbreviations: AFP=alpha fetoprotein; ALT=alanine aminotransferase; AST=aspartate transaminase; CI=confidence interval; GGT=gamma-glutamyltransferase; HBsAg=hepatitis B surface antigen; HR=hazard ratio; LMR= lymphocyte-to-monocyte ratio; NA=not adopted; OS= overall survival; SIS=systemic inflammation score; TB= total bilirubin; TNM stage= tumor--node--metastasis stage; TTR= time to recurrence.

^1^Analysed as a continuous variable.

^2^Analysis including LMR and GGT (omitting SIS).

^3^Analysis including SIS (omitting LMR and GGT).

Comparation of predictive ability of SIS and other inflammatory parameters {#s2_7}
--------------------------------------------------------------------------

Predictive ability of the SIS was compared with other inflammatory parameters(GGT, LMR, NLR and PLR) by ROC curves (Figure [3](#F3){ref-type="fig"}). The discrimination ability was compared by the area under the receiver operating characteristic curve(AUC) for OS (Table [3](#T3){ref-type="table"}). The AUC for the SIS was 0.682 (95% CI, 0.618-0.746), which was the strongest factor among inflammatory parameters (GGT, LMR, NLR and PLR) for predicting survival in patients with HCC.

![Predictive ability of the SIS was compared with other inflammatory parameters by ROC curves](oncotarget-08-79366-g003){#F3}

###### Comparation of predictive ability of SIS and other inflammatory parameters

        AUC(95%CI)           *P*
  ----- -------------------- ---------
  SIS   0.682(0.618-0.746)   \<0.001
  GGT   0.637(0.570-0.703)   \<0.001
  LMR   0.614(0.547-0.681)   0.001
  NLR   0.602(0.535-0.670)   0.004
  PLR   0.558(0.490-0.627)   0.097

Abbreviations: AUC=area under the receiver operating characteristic curve; CI=confidence interval; GGT=gamma-glutamyltransferase; LMR=lymphocyte-to-monocyte ratio; NLR=neutrophil-to-lymphocyte ratio; PLR=platelet-to-lymphocyte ratio; SIS=systemic inflammation score.

DISCUSSION {#s3}
==========

Links between cancer and inflammation were first described in the nineteenth century. Nowadays, increasing evidence indicating systemic inflammatory response plays an important role in cancer progression \[[@R5]\]. Markers based on systemic inflammation, such as the NLR and PLR, have been reported to be useful in predicting the outcome of cancer patients \[[@R6]-[@R13]\]. In the present study, a novel systemic inflammation score (SIS) was constructed based on preoperative serum GGT and LMR. The data indicated GGT, LMR and SIS were independent predictors of survival and recurrence for patients with HCC after hepatectomy. Our results revealed that an elevated preoperative LMR was significantly associated with increased OS and TTR, whereas an elevated preoperative GGT were significantly associated with inferior OS and TTR. The exact reason for the association of elevated preoperative GGT or low LMR with poor prognosis in malignant tumor patients remains largely unclear.

Firstly, our study identified GGT as a prognostic marker for patients with HCC after hepatectomy. GGT is a key enzyme that plays an important role in the metabolism of glutathione, and it is also correlated with tumorigenesis \[[@R26]\]. GGT may induced DNA instability and subsequent oncogenesis, leading to the death of normal liver cells or the loss of normal liver function \[[@R27]\]. A series of studies have suggested that serum GGT was a marker of oxidative stress \[[@R28]\]. The pro-oxidant activity of GGT may contribute to the persistent oxidative stress described in cancer and modulate processes involved in tumor progression \[[@R29]\]. As a consequence, recent studies suggested elevated GGT was a promising biomarker for poor OS of HCC patients who underwent hepatic resection \[[@R23]\], radiofrequency-ablation treatment \[[@R24]\] or transcatheter arterial chemoembolization \[[@R25]\]. The molecular mechanisms of the association between GGT and poor prognosis of HCC need further study.

The second part of the study was successful in defining the utility of the LMR as a prognostic indicator in HCC patients after hepatectomy. Lymphocytes can exert an anti-tumor effect by inhibiting tumor cell proliferation and migration \[[@R5],[@R30]\]. As a consequence, a low lymphocyte count might result in a weak antitumor reactions and could predict a poor clinical outcome \[[@R31]\]. On the other hand, monocytes are a type of white blood cells that can further differentiate into a range of tissue macrophages and dendritic cells \[[@R32]\]. Monocytes were reported to promote tumorigenesis through local immune suppression \[[@R33]\]. In addition, monocytes can differentiate into tumor associated macrophages (TAMs), which mostly promote tumor growth and may be obligatory for angiogenesis, invasion, and metastasis \[[@R34]\]. Macrophage could also promote the growth, migration and metastasis of tumor cells by releasing some soluble factors \[[@R5], [@R35]\]. Previous studies indicated elevated macrophage content was associated with poor clinical outcome \[[@R36]-[@R38]\]. Hence, an elevated absolute monocyte count may predict poor prognosis in tumor patients. LMR, a combination of lymphocytes and monocytes, may represent a balance in host immunity against malignancy has enhanced prognostic value. Previous studies of hematologic malignancies suggested that an increased LMR promised a good prognosis \[[@R15],[@R16]\]. More recently, some reports indicated the prognostic significance of LMR in patients with solid tumors, including gastric \[[@R17]\], colon \[[@R18]\], bladder \[[@R19], [@R20]\], renal \[[@R21]\] and lung cancers \[[@R22]\].

Our results indicated the predictive ability of GGT and LMR is stronger than other inflammatory parameters (NLR and PLR). Therefore, we combine these two prognostic markers to construct SIS, assuming that SIS might have a combined predictive effect of GGT and LMR. SIS is a convenient biomaker because serum GGT and complete blood count are routinely measured before surgery in our clinical practice. In the future, basic research may provide an understanding of its molecular mechanisms that may become potential therapeutic targets.

We assessed the association of LMR, GGT and SIS with clinicopathological characteristics. It is worth mentioning that GGT were significantly associated with male, ALT and AST in our study, which was in line with previous studies. Previous studies has demonstrated a sex difference in GGT level \[[@R39], [@R40]\] and it has been suggested that the lower level of GGT for women is likely to be of a physiological nature. Moreover, fatty liver occurred more frequently in men than women and the distributions of concentrations of liver enzymes differ between men and women \[[@R41]\]. Recommended cutoffs of abnormal liver enzymes were significantly higher for men than women \[[@R42]\].

The present study had several limitations that require discussion. Firstly, the present study was a retrospective design with single-center and missing variables or selection bias are possible because of its retrospective nature. Secondly, peripheral blood cell counts were performed only once, which might cause bias. In addition, C-reactive protein (CRP) was not gathered in our analyses because it was not routinely measured in our clinical practice. Large-scale prospective studies are warranted to substantiate and validate our results.

In conclusion, our results demonstrated low preoperative LMR and high preoperative GGT were associated with a poor prognosis in HCC patients after hepatectomy. SIS, constructed based on preoperative GGT and LMR, is an easily measured and novel prognostic marker that was significantly correlated with OS and TTR. Our results confirmed that the SIS qualifies as a novel prognostic predictor of HCC patients after curative resection.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

A total of 271 patients with HCC who underwent curative hepatic resection at the Liver Cancer Institute of Zhongshan Hospital (Fudan University, Shanghai, China) between 2008 and 2011 were enrolled after informed consent. Patients who underwent preoperative therapy, such as transarterial chemoembolization, radiofrequency ablation or percutaneous ethanol injection, were excluded from this study. Ethical approval was obtained from the research ethics committee of Zhongshan Hospital, and written informed consent was obtained from each patient.

Follow-up {#s4_2}
---------

The patient follow-up and postoperative treatment were administrated as described previously according to our established guidelines \[[@R43]\]. All patients were regularly screened for recurrence through monitoring of serum AFP, abdomen ultrasonography, and chest x-ray every 1 to 6 months according to the postoperative time. For patients with test results suggestive of recurrence, computed tomography and/or magnetic resonance imaging were used to verify the recurrence. TTR was defined as the interval between the date of surgery and the first recurrence, or from the date of surgery to the date of last follow-up patients without recurrence. OS was defined as the interval between surgery and death, or the interval between surgery and the last observation for surviving patients. Patients who were still alive or recurrence-free were censored at the last follow-up date.

Statistical analysis {#s4_3}
--------------------

Data are expressed as the mean ± standard deviation. ROC curve analysis was applied to determine the optimal cut-off level for LMR as predictor of OS. Prediction accuracy was evaluated with area under the ROC curve. The associations of LMR, GGT and SIS with clinicopathological characteristics were examined using the χ^2^ test or Fisher exact test. The Cox proportional hazards regression model was applied to perform univariate and multivariate analyses, and those variables that achieved statistical significance in the univariate analysis were entered into the multivariable analysis. The Kaplan-Meier method with log-rank test was used to compare survival curves. All statistical analyses were performed using the Statistical Package for Social Sciences version 19.0 (SPSS Inc, Chicago, IL). A two-sided *P*-value of \< 0.05 was considered statistically significant in all tests.
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